Patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) and stenting initially require triple antithrombotic therapy according to the current ESC 2010 guidelines. The purpose of this study was to assess guidelines adherence and detect predictive factors of the prognosis linked to ESC guidelines adherence and clinical characteristics of this population.
Background:
Patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) and stenting initially require triple antithrombotic therapy according to the current ESC 2010 guidelines. The purpose of this study was to assess guidelines adherence and detect predictive factors of the prognosis linked to ESC guidelines adherence and clinical characteristics of this population.
Methods: AF patients referred for PCI with stenting were enrolled since the year 2011 to 2013. Prescription and chronology of the antithrombotic treatment (AT), occurrence of bleeding, myocardial ischemia, stroke and death were obtained by screening hospitalization reports and phone call with standardized questions during follow-up.
Results:
Among 259 AF patients with PCI and stenting (age 76±10 years; CHA2DS2-VASc score 4.3 ± 1.7), 40% had acute coronary syndrome and 60% had elective PCI. During 633 ± 352 days follow-up, 53/156 (34%) of those admitted for elective PCI were guidelines adherent, whilst they were 10/49 (20%) for non ST elevation myocardial infarction (NSTEMI) and 8/54 (15%) for STEMI. Permanent AF (OR, 0.45; 95%CI 0.23-0.89; p=0.02), history of valvular heart disease (OR 0.51; 95%CI 0.26-0.98; p=0.04), heart failure (OR 0.49; 95%CI 0.25-0.94; p=0.03) and use of OAC before hospitalization (OR 0.48; p=0.04) were associated with guidelines adherence. OAC and APT underuse were associated with an increased risk of death (OR 3.73; p=0.005 and OR 7.35, p=0 .0009 respectively) whereas APT overtreatment was associated with a significant lower rate of death (OR 0.23, 95% CI 0.08-0.59, p=0.002).
Conclusion:
Guidelines for antithrombotic therapy in patients with AF who undergo PCI and stent implantation are still poorly followed in clinical practice. OAC underused was associated with an increased risk of death in this population. Tissue activation of proteolysis is involved in progressive dilation and dissection of human thoracic aneurysms of ascending aorta (TAA). Vascular smooth muscle cells (VSMC) limit possible proteolytic wall injury by producing antiproteases, among which is protease nexin-1 (PN-1) . PN-1 is a tissue serpin expressed by VSMC, able to inhibit plasmin activities by forming complexes. The main objective was to test whether human VSMC can clear plasmin/PN-1 complex through an LRP1-dependent mechanism.
We have explored the expression of PN-1, t-PA and LRP-1 in human tissue and cultured VSMC of TAA compared with healthy aorta (control). PN-1, t-PA and LRP-1 mRNA were overexpressed in medial extracts of TAA compared with control. Both PN-1 and LRP-1 protein were overexpressed in cultured VSMC from TAA as compared to control whereas for t-PA there was no difference in protein expression between TAA and control. We have studied the localisation of PN-1/plasmin and LRP-1 in TAA. Intracellular presence of plasmin, PN-1 and LRP-1 in VSMC in human TAA was detected. We used cultured VSMC to study their abilitiy to endocytose PN-1 or PN-1/ plasmin complexes. VSMC endocytose PN-1 and PN-1/plasmin complexes but not plasmin.
Our results suggest that PN-1, t-PA and LRP-1 are increased in order to protect the arterial wall from protease injury in TAA.
Delphinidin and calcium signaling in human T lymphocytes: a basis to elucidate pathways leading to proliferation and apoptosis
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Delphinidin, an anthocyanin present in red wine, has been reported to exert vasculoprotective properties due to its vasodilatory and antioxidant effects at the level of the endothelium. However, the effect of delphinidin on cells involves in inflammation in cardiovascular diseases remains unknown. We have investigated the effect of delphinidin on the proliferation and apoptosis of T lymphocytes with respect to calcium signaling. Human T cells were isolated from blood of healthy patients. Proliferation was assessed using CyQUANT® NF Cell Proliferation Assay Kit and apoptosis by flow cytometry. Calcium signaling was analyzed using Fluo-4 probe and the mechanisms were depicted using appropriate drugs. Delphinidin did not modify basal proliferation but it was able to decrease the phytohemagglutinin (PHA)-induced proliferation. Inhibitors of capacitative entry and estrogen receptor antagonist, fulvestrant, but not the NO-synthase inhibitor prevented the effect of delphinidin. In addition, delphinidin reduced actinomycin D-induced apoptosis via a mechanism sensitive to capacitative entry inhibitors. Interestingly, delphinidin decreased the ability of thapsigargin to increase both calcium release and entry. The effect of delphinidin was sensitive to capacitative entry inhibitors and partially prevented by fulvestrant but not by the NO synthase inhibitor. Immunohistochemistry analysis showed that delphinidin reduced membrane translocation of STIM-1, a principal step in capacitative entry activation through « calcium release activated channels » CRAC. Together, these data suggest that delphinidin attenuates T lymphocyte activation via multiple cellular targets on the regulation of calcium signaling via estrogen antagonist sensitive and insensitive pathways. The consequence of which results in inhibition of both proliferation and apoptosis. These effects concur to the protective effect of delphinidin on processes leading to inflammation associated with T lymphocyte activation. 
